A carregar...
Suvorexant improves intractable nocturnal enuresis by altering sleep architecture
Little is known about sleep-based approaches to the treatment of nocturnal enuresis (NE). This report is the first to describe the successful use of suvorexant, an orexin receptor antagonist, in a 12-year-old boy with intractable NE. With suvorexant, the frequency of NE gradually decreased from 14 o...
Na minha lista:
| Publicado no: | BMJ Case Rep |
|---|---|
| Autor principal: | |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BMJ Publishing Group
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7970267/ https://ncbi.nlm.nih.gov/pubmed/33727289 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bcr-2020-239621 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|